Agendia Unveils Clinical Validation of AI-Driven Digital Pathology Approach
The investigational AI-driven digital assay demonstrated high concordance with Read More
Agendia to Showcase New Research on AI-Driven Digital Pathology at ESMO 2026
Podium presentation by Co-Founder and Chief Research Officer Laura Read More
Largest Real-World Evidence Study in Early-Stage Breast Cancer; FLEX Surpasses 25,000 Patients
Agendia’s landmark FLEX Study reaches a major enrollment milestone, Read More
Agendia Announces Definitive, Mandatory Swiss Health Insurance Reimbursement for MammaPrint
Effective 1 July 2026, Switzerland’s FOPH completes its review Read More
Genomic Profiling with MammaPrint + BluePrint Predicts Anthracycline Chemotherapy Benefit and Guides Personalized Treatment Selection in HR+HER2- Early-Stage Breast Cancer GalleryGenomic Profiling with MammaPrint + BluePrint Predicts Anthracycline Chemotherapy Benefit and Guides Personalized Treatment Selection in HR+HER2- Early-Stage Breast Cancer
Genomic Profiling with MammaPrint + BluePrint Predicts Anthracycline Chemotherapy Benefit and Guides Personalized Treatment Selection in HR+HER2- Early-Stage Breast Cancer
FLEX Study data shows that patients with MammaPrint High Read More
- Agendia to Present New FLEX Study Data at ASCO 2026 Supporting NCCN Clinical Practice Guidelines in Oncology Update Recognizing MammaPrint for Guiding Anthracycline Use in Early-Stage Breast Cancer Gallery
Agendia to Present New FLEX Study Data at ASCO 2026 Supporting NCCN Clinical Practice Guidelines in Oncology Update Recognizing MammaPrint for Guiding Anthracycline Use in Early-Stage Breast Cancer
Agendia to Present New FLEX Study Data at ASCO 2026 Supporting NCCN Clinical Practice Guidelines in Oncology Update Recognizing MammaPrint for Guiding Anthracycline Use in Early-Stage Breast Cancer
Additional research highlights integration of BluePrint molecular subtyping and Read More
- Agendia to Present New FLEX Study Data at ASBrS 2026 Confirming the Consistent Performance of MammaPrint + BluePrint Across Diverse Racial Groups in Genomically Basal-Type Breast Cancer Gallery
Agendia to Present New FLEX Study Data at ASBrS 2026 Confirming the Consistent Performance of MammaPrint + BluePrint Across Diverse Racial Groups in Genomically Basal-Type Breast Cancer
Agendia to Present New FLEX Study Data at ASBrS 2026 Confirming the Consistent Performance of MammaPrint + BluePrint Across Diverse Racial Groups in Genomically Basal-Type Breast Cancer
Multivariate analyses reveal that pathologic complete response is associated Read More
- Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint® and BluePrint® at the 2026 ESMO Breast Cancer Annual Congress Gallery
Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint® and BluePrint® at the 2026 ESMO Breast Cancer Annual Congress
Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint® and BluePrint® at the 2026 ESMO Breast Cancer Annual Congress
Poster presentations highlight the prognostic value of MammaPrint + Read More
- Genomic Profiling with MammaPrint ® + BluePrint ® Identifies Aggressive Tumor Subtypes Driving Racial Survival Disparities in HR+/HER2– Early-Stage Breast Cancer Gallery
Genomic Profiling with MammaPrint ® + BluePrint ® Identifies Aggressive Tumor Subtypes Driving Racial Survival Disparities in HR+/HER2– Early-Stage Breast Cancer
Genomic Profiling with MammaPrint ® + BluePrint ® Identifies Aggressive Tumor Subtypes Driving Racial Survival Disparities in HR+/HER2– Early-Stage Breast Cancer
Multicenter study of over 1000 females with breast cancer, Read More
Agendia Announces NCCN Guideline Update Recognizing MammaPrint to Guide Personalized Anthracycline Use in HR+/HER2- Early‑Stage Breast Cancer
Agendia Announces NCCN Guideline Update Recognizing MammaPrint to Guide Read More
